Lam Research Corp. Stock Rallies 3.5%, Outperforms Peers
Dow Jones2026/10/01 20:35This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Lam Research Corp. advanced 3.5% to $340.10 on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.2% to 7,666.45 and the Dow Jones Industrial Average remaining mostly unchanged at 50,926.56.
This was the stock's third consecutive day of gains.
Lam Research Corp. closed 22.4% short of its 52-week high of $438.50, which the company achieved on June 30th.
The stock outperformed some of its peers, as Advanced Micro Devices Inc. rose 0.6% to $615.73, Applied Materials Inc. rose 3.5% to $529.30, and Analog Devices Inc. rose 1.99% to $404.60.
Trading volume totaled 8.5 million, compared to the 50-day average of 9.4 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 01, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Simwon America (SWA.US) applies for Nasdaq IPO, plans to raise up to $50 million
Simwon America, a manufacturer of structural components for electric vehicles, filed for an IPO with the U.S. Securities and Exchange Commission (SEC) last Friday, aiming to raise up to $50 million. The company is a spinoff of Korea’s MS Autotech.
Sui Foundation Invests $30M in DATA Network as It Moves to Sui post-167040 post-167040 post-167040

Equities: Stable oil and yields support stock gains - Danske Bank
Dental caries treatment provider vVardis (VVVV.US) submits US IPO application, expected to raise 200 million USD
vVardis Holding filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) last Friday. The company focuses on self-developed non-invasive restorative therapies for the early treatment of dental caries. The IPO is expected to raise 200 millions USD.